Loading organizations...
OneDrop is a technology company.
One Drop develops a digital health platform for chronic condition management, primarily focusing on diabetes. The platform integrates mobile technology, data science, and artificial intelligence to deliver personalized insights and support. It analyzes user-generated data to provide predictive health forecasts and adaptive coaching, aiming to simplify daily self-management.
Jeffrey Dachis, co-founder of Razorfish, established One Drop in 2015. His founding insight stemmed from his personal experience managing a chronic condition, recognizing the need for accessible, data-driven self-care. Dachis's background in digital innovation directly shaped the company's technology-centric approach to health solutions.
One Drop’s product serves individuals managing chronic conditions like diabetes and hypertension, who seek to improve their health outcomes digitally. The company’s vision centers on transforming chronic disease management by making evidence-based, personalized care universally accessible. It ultimately aims for a future where advanced health technology enables proactive and preventative self-care.
OneDrop has raised $42.7M across 2 funding rounds.
OneDrop has raised $42.7M in total across 2 funding rounds.
OneDrop has raised $42.7M in total across 2 funding rounds.
OneDrop's investors include Jeanne Kehren, RRE Ventures, 2048 Ventures, Andreessen Horowitz, Authentic Ventures, BoxGroup, Chemistry VC, Company Capital, CRV, Forerunner Ventures, Hanabi Capital, Idealab.
One Drop is a New York-based precision health company founded in 2015 that builds a digital platform for managing chronic conditions like diabetes, prediabetes, high blood pressure, and high cholesterol.[1][2][3] It serves individuals worldwide through an AI-powered mobile app that integrates continuous glucose monitoring (CGM), blood glucose meters, insulin pumps, personalized coaching from certified health professionals, and FDA-cleared connected devices, solving the problem of reactive chronic care by enabling proactive, data-driven decisions to improve health outcomes and reduce costs.[1][2][3][4] With $154.4 million in total funding, $26 million in 2024 revenue, and over 25 billion biometric data points collected, One Drop demonstrates strong growth momentum, including a 450% revenue increase from 2017-2020 (ranking #287 on Deloitte's 2021 Technology Fast 500) and expansion post-acquisition by Transom Capital Group in early 2024.[1][3][4][6]
One Drop was founded in 2015 in New York City by entrepreneurs leveraging expertise in mobile technology, data science, and healthcare to address gaps in chronic disease management.[2][3][4] The idea emerged from recognizing the need for a unified platform that combines device data logging (e.g., glucose levels from meters, CGMs, and pumps) with predictive analytics and behavioral coaching, moving beyond fragmented tools to empower users with actionable insights on factors like food, insulin, and exercise.[2][4] Early traction built through rapid adoption of its app, amassing billions of data points and achieving milestones like surpassing 25 billion biometric data points by 2021, while securing $154.4 million in funding across six rounds, including a $64 million latest raise.[3][4] A pivotal moment came with its 2024 acquisition by Transom Capital Group, aligning with scaled growth strategies.[1]
One Drop rides the wave of precision health and digital therapeutics, capitalizing on AI, wearables, and big data to shift chronic care from episodic to continuous and predictive amid rising global prevalence of diabetes and comorbidities.[1][2][3] Timing aligns with post-pandemic telehealth acceleration, regulatory nods for connected devices, and payer demands for cost-effective outcomes, bolstered by its 25 billion+ data trove for superior ML models.[1][4] Market forces like aging populations, CGM adoption, and value-based care favor its model, influencing the ecosystem by setting benchmarks for integrated platforms that empower patients and providers while competing in a crowded field of diabetes managers like Glooko and Omada.[2][3]
One Drop is poised for accelerated global expansion under Transom Capital, leveraging its data moat and AI edge to penetrate emerging markets and broaden beyond diabetes into hypertension and cholesterol management.[1][3] Trends like multimodal sensing, generative AI for coaching, and partnerships with payers/health systems will shape its path, potentially evolving influence through B2B offerings for providers. As chronic care digitizes, One Drop's proactive platform positions it to redefine accessible health empowerment, building on its foundational mission to transform lives through data-driven precision.[1][2]
OneDrop has raised $42.7M across 2 funding rounds. Most recently, it raised $34.7M Series C in August 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 25, 2020 | $34.7M Series C | Jeanne Kehren | |
| Jun 1, 2015 | $8.0M Series A | RRE Ventures | 2048 Ventures, Andreessen Horowitz, Authentic Ventures, BoxGroup, Chemistry VC, Company Capital, CRV, Forerunner Ventures, Hanabi Capital, Idealab, IVP, Lampros Capital Partners, Lerer Hippeau, RTP Ventures, Saga, Sequoia Capital, South Park Commons, Stellar Capital, Yext, Adam D'Angelo, Alexander Sacerdote, Drew Houston, Frederic Kerrest, Jeff Bezos, John Collison, Joshua Reeves, Tien Tzuo, Capital Factory, LAUNCH Fund, Neu Ventures |